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ABSTRACT
Clonidine has been shown effective in 
reducing sympathetic hyperactivity in 
neonatal abstinence syndrome (NAS). The 
aim of this study was to analyze clinical 
and laboratory characteristics of a group of 
newborns treated with clonidine for NAS 
due to maternal drug addiction and due to 
withdrawal from opioid analgesic therapy. 
Only one full–term newborn presented 
with metabolic acidosis and hyperkalemia; 
in others no clinical or laboratory adverse 
effects were detected. This report empha-
sizes the importance of alertness to poten-
tial adverse effects of clonidine therapy, 
and discusses possible pathophysiological 
aspects of hyperkalemia and metabolic aci-
dosis during treatment for NAS.
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INTRODUCTION
Although clonidine is generally approved 
only as an adjunctive treatment for opioid 
withdrawal, it has been shown as an ef-
fective medicine in reducing sympathetic 
hyperactivity in neonatal abstinence syn-
drome (NAS). (1) Many autonomic symp-
toms of opioid withdrawal like nausea, 
vomiting, cramps, sweating, tachycardia 
and hypertension, result from the loss 
of opioid suppression of locus coeruleus 
during NAS. By activating presynaptic 
alpha2-receptors, clonidine reduces in-
creased sympathetic tone via a negative 
feedback mechanism. The opioid NAS pa-
tients treated with clonidine in addition to 
reduced withdrawal symptoms benefit also 
from shorter duration of treatment and 
hospitalisation and are free of cardiovascu-
lar or sedation adverse effects. (2)
CASE SERIES
We analyzed clinical and laboratory find-
ings of seven patients who were treated 
with clonidine because of NAS at the 
Department of Neonatology, Division of 
Pediatrics, University Medical Centre Lju-
bljana, Slovenia, from April 2013 to March 
2014. Two patients were treated for NAS 
because of maternal drug addiction and 
five because of withdrawal from opioid an-
algesic therapy during intensive care (table 
1). Routine daily controls of blood gases 
and ionogram revealed no abnormali-
ties in six children, while in one- treated 
with clonidine for NAS due to maternal 
substitution therapy with methadone- hy-
perkalemia and metabolic acidosis was 
noticed. He was a full–term infant who 
developed NAS 48 hours after birth. The 
Finnegan score was 15 in three consecutive 
assessments and therapy with clonidine 1.1 
µg/kg/6h was started orally on the third 
day of life (PD3). (3) Before treatment 
with clonidine urine output was 3–4 mL/
kg/h; blood pressure and laboratory values 
were within normal limits. On the third 
day after introduction of clonidine (PD6), 
diuresis rose to 8 mL/kg/h; blood urea and 
sodium concentrations were found to be 
in the high normal values, but creatinine, 
potassium and blood gas analysis were 
still normal. The boy was fed with formula 
milk, received additional hydration but no 
potassium supplementation. Blood urea 
and sodium concentrations normalized 
but after nine days of clonidine therapy 
(PD12) metabolic acidosis with hyper-
kalemia (pH 7.35, pCO2 4.04 kPa, HCO3 
16.7 mmol/L, BE -9 mEq/L, anion gap 
14.5 mEq/L, K 6.6 mmol/L, venous blood) 
was found; ECG showed peaked T waves. 
Glucose by intravenous infusion was intro-
duced but as the potassium level reached 
7.2 mmol/L the fast acting insulin was 
started and clonidine stopped (PD12). Po-
tassium levels normalized three days after 
abrupt clonidine withdrawal (PD15). The 
Finnegan score after clonidine withdrawal 
was under 8 so additional therapies were 
not introduced. The boy was discharged 
home at the age of 18 days in a stable con-
dition.
DISCUSSION
Hyperkalemia with metabolic acidosis, 
which we observed in one of our patients 
treated with clonidine, is a potentially le-
thal condition since it can provoke life–
threatening arrhythmias. In the broad 
differential diagnosis of acid–base and 
electrolyte imbalance, the plausible eti-
ology could be probable or possible ad-
verse reaction to clonidine, according to 
Naranjo’s algorithm. (4) In a larger cohort, 
in a randomized, double–blind, controlled 
trial, where clonidine was added to opioid 
replacement therapy for opioid NAS, no 
hypertension, hypotension, bradycardia, 
or haemoglobin desaturation were ob-
served; one infant developed supraven-
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tricular tachycardia and three children 
died in the first two months of life. The 
reported causes of death were myocarditis, 
sudden infant death syndrome, and homi-
cide and it is not known whether clonidine 
contributed to the deaths. (5) Contrary to 
our study, the authors did not report any 
laboratory findings in the patient group 
studied.
Clonidine acts as an 2–adrenoceptor ago-
nist at central and peripheral 2–adreno-
ceptors. In addition to its central effect, 
it also acts via postsynaptic alpha2A-C–
adrenoreceptor subtypes located in the 
distal tubules of the human kidney. There-
fore, the kidney is subjected to a decreased 
sympathetic tone that causes an increase in 
renal blood flow, which possibly presented 
with polyuria in our patient. Clonidine–
mediated diminished sympathetic tone 
also causes decreased plasma renin activ-
ity and consequently reduces aldosterone 
secretion, which prevents the excretion of 
K+. This effect could be potentiated by al-
dosterone–resistance, which often occurs 
in newborns. (6) In addition, the lack of 
sympathetic tone also decreases extrarenal 
disposal of potassium, which additionally 
could lead to hyperkalemia. In our patient, 
hyperkalemia did not reappear after dis-
continuation of clonidine, so we suppose 
that laboratory findings after 9 days of 
therapy with clonidine indicated the pres-
ence of type 4 renal tubular acidosis where 
hyperkalemia is the cardinal feature, and 
acidosis is mild when present. (7) Meta-
bolic acidosis, which has been previously 
described as an adverse effect of clonidine, 
resolved spontaneously in all cases. (8)
In conclusion, we assume that metabolic 
acidosis type 4 with hyperkalemia in one of 
our patients was due to 1) decreased aldos-
terone secretion induced by clonidine, and 
2) physiological resistance to aldosterone 
in human newborns, so we recommend 
regular controls of potassium blood levels 
after introducing clonidine for NAS.





















































































































16 1 7 2,2µg/6 h normal normal normal optimal, 44
AGA, appropriate for gestational age; hyperK, hyperkalemia; LGA, large for gestational age; SGA, small for gestational age.
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